RPCA
AKBA icon

Running Point Capital Advisors’s Akebia Therapeutics AKBA Stock Holding History

Running Point Capital Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-10,000
Closed -$3K – 212
2022
Q3 		$3K Hold
10,000
– – ﹤0.01% 212
2022
Q2 		$4K Hold
10,000
– – ﹤0.01% 216
2022
Q1 		$7K Buy
+10,000
New +$21.4K ﹤0.01% 206

Other funds holding AKBA

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OCM
Ovata Capital Management Hong Kong $715M AUM 19.57% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Running Point Capital Advisors's AKBA Position: Q4 2022 in Review

Running Point Capital Advisors sold out of Akebia Therapeutics (AKBA) in Q4 2022, closing a stake of 10,000 shares — an estimated $3K sold.

Running Point Capital Advisors first reported a position in AKBA in Q1 2022 and held it in 3 quarters. The position peaked at $7K in Q1 2022. 75 funds tracked by Wall St. Rank hold AKBA as of Q4 2022.

  • Running Point Capital Advisors reported no remaining Akebia Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Running Point Capital Advisors sold 10,000 Akebia Therapeutics shares in Q4 2022, an estimated $3K.
  • Running Point Capital Advisors first reported a position in Akebia Therapeutics in Q1 2022 and held it in 3 quarters.
  • Running Point Capital Advisors's Akebia Therapeutics position peaked at $7K in Q1 2022.
  • 75 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2022.

Based on Running Point Capital Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.